Aprepitant (APRT), a selective neurokinin 1 antagonist, is clinically used in the prevention of acute and delayed chemotherapy-induced nausea and vomiting. The low solubility of APRT, which limits its oral bioavailability, is overcome by nanonization. This study aimed to design and evaluate novel in vitro and in vivo chitosan (CS)–polyethylene glycol (PEG)-coated cyclodextrin (CD) nanoparticles and nanocapsules to enhance the solubility and oral bioavailability of APRT.
A novel amphiphilic CD derivative with alkyl chains of 9 carbons (ACD-C9) was synthesized to form nanoparticles and nanocapsules by using nanoprecipitation. The nanocarriers were coated with the CS–PEG conjugate to increase their biological interaction with cell membranes via the positive charge and penetration-enhancer properties of CS. The nanosystems were evaluated for particle size, surface charge, drug loading, imaging, release, cell culture, and oral bioavailability in an animal model.
The CS–PEG-coated nanosystems had particle size of 400–550 nm, a narrow polydispersity index, positive zeta potential, and favorable drug loading (55 and 93% for nanoparticles and nanocapsules, respectively). Sustained release was observed within 24 h. Blank nanoparticles and nanocapsules were non-cytotoxic against the L929 cell line. The intestinal permeability of the nanocarriers was 2–threefold (2-3 fold) higher than that of the drug solution, and the nanocapsules afforded the highest APRT permeability through Caco-2 cells. Oral bioavailability studies in rats revealed comparable degree of drug absorption between nanocapsules and commercial APRT products.
Oral ACD-C9 nanocapsules have the potential for the treatment of chemotherapy-induced nausea and vomiting.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Adel N (2017) Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manage Care 23:S259–S265
Aktas Y, Andrieux K, Alonso MJ, Calvo P, Gursoy RN et al (2005) Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm 298:378–383
Aktas Y, Yenice K, Bilensoy E, Hincal AA (2015) Amphiphilic cyclodextrins as enabling excipients for drug delivery and for decades of scientific collaboration: tribute to a distinguished scientist, French representative and friend—a historical perspective. J Drug Deliv Sci Technol 30:261–265
Attari Z, Kalvakuntla S, Reddy MS, Deshpande M, Rao CM et al (2015) Formulation and characterisation of nanosuspensions of BCS class II and IV drugs by combinative method. J Exp Nanosci 11:276–288
Bilensoy E, Hincal AA (2009) Recent advances and future directions in amphiphilic cyclodextrin nanoparticles. Expert Opin Drug Deliv 6:1161–1173
Caliph SM, Charman WN, Porter CJ (2000) Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci 89:1073–1084
Charman WN (2000) Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J Pharm Sci 89:967–978
Charmsaz S, Collins DM, Perry AS, Prencipe M (2019) Novel strategies for cancer treatment: highlights from the 55th IACR Annual Conference. Cancers (Basel) 11:1125
Chen X, Wang T, Lu M, Zhu L, Wang Y et al (2014) Preparation and evaluation of tilmicosin-loaded hydrogenated castor oil nanoparticle suspensions of different particle sizes. Int J Nanomed 9:2655–2664
Chorny M, Fishbein I, Danenberg HD, Golomb G (2002) Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Release 83:389–400
des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V (2006) Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 116:1–27
Emami J, Boushehri MS, Varshosaz J (2014) Preparation, characterization and optimization of glipizide controlled release nanoparticles. Res Pharm Sci 9:301–314
Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S (1989) Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55:R1–R4
Gharibzahedi SMT, Jafari SM (2017) Nanocapsule formation by cyclodextrins. In: Jafari SM (ed) Nanoencapsulation technologies for the food and nutraceutical industries. Academic Press, Cambridge, pp 187–261
Groo AC, Saulnier P, Gimel JC, Gravier J, Ailhas C et al (2013) Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery. Int J Nanomed 8:4291–4302
Hamidi M, Azadi A, Rafiei P (2008) Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev 60:1638–1649
He M, Zhong C, Hu H, Jin Y, Chen Y et al (2019) Cyclodextrin/chitosan nanoparticles for oral ovalbumin delivery: preparation, characterization and intestinal mucosal immunity in mice. Asian J Pharm Sci 14:193–203
Ibrahim MA, Preuss CV (2020) Antiemetic Neurokinin-1 receptor blockers. StatPearls. StatPearls Publishing, Treasure Island, FL
Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MN (2009) Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res 26:492–501
Kamboj S, Rana V (2016) Formulation optimization of aprepitant microemulsion-loaded silicated corn fiber gum particles for enhanced bioavailability. Drug Dev Ind Pharm 42:1267–1282
Kamboj S, Sharma R, Singh K, Rana V (2015) Aprepitant loaded solid preconcentrated microemulsion for enhanced bioavailability: a comparison with micronized Aprepitant. Eur J Pharm Sci 78:90–102
Karimi Z, Abbasi S, Shokrollahi H, Yousefi G, Fahham M et al (2017) Pegylated and amphiphilic chitosan coated manganese ferrite nanoparticles for pH-sensitive delivery of methotrexate: synthesis and characterization. Mater Sci Eng C Mater Biol Appl 71:504–511
Khattab WM, Zein El-Dein EE, El-Gizawy SA (2020) Formulation of lyophilized oily-core poly-E-caprolactone nanocapsules to improve oral bioavailability of Olmesartan Medoxomil. Drug Dev Ind Pharm 46:795–805
Loftsson T, Brewster ME (1996) Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 85:1017–1025
Loftsson T, Duchene D (2007) Cyclodextrins and their pharmaceutical applications. Int J Pharm 329:1–11
Loftsson T, Brewster ME, Másson M (2004) Role of cyclodextrins in improving oral drug delivery. Am J Drug Deliv 2:261–275
Mora-Huertas CE, Fessi H, Elaissari A (2010) Polymer-based nanocapsules for drug delivery. Int J Pharm 385:113–142
Nurgali K, Jagoe RT, Abalo R (2018) Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front Pharmacol 9:245
Olver I, Shelukar S, Thompson KC (2007) Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomed 2:13–18
Palacio J, Agudelo NA, Lopez BL (2016) PEGylation of PLA nanoparticles to improve mucus-penetration and colloidal stability for oral delivery systems. Curr Opin Chem Eng 11:14–19
Parrott N, Lukacova V, Fraczkiewicz G, Bolger MB (2009) Predicting pharmacokinetics of drugs using physiologically based modeling-application to food effects. Aaps J 11:45–53
Peltier S, Oger JM, Lagarce F, Couet W, Benoit JP (2006) Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 23:1243–1250
Penalva R, Esparza I, Morales-Gracia J, Gonzalez-Navarro CJ, Larraneta E et al (2019) Casein nanoparticles in combination with 2-hydroxypropyl-beta-cyclodextrin improves the oral bioavailability of quercetin. Int J Pharm 570:118652
Presas E, McCartney F, Sultan E, Hunger C, Nellen S et al (2018) Physicochemical, pharmacokinetic and pharmacodynamic analyses of amphiphilic cyclodextrin-based nanoparticles designed to enhance intestinal delivery of insulin. J Control Release 286:402–414
Ran F, Lei W, Cui Y, Jiao J, Mao Y et al (2018) Size effect on oral absorption in polymer-functionalized mesoporous carbon nanoparticles. J Colloid Interface Sci 511:57–66
Ren L, Zhou Y, Wei P, Li M, Chen G (2014) Preparation and pharmacokinetic study of aprepitant-sulfobutyl ether-beta-cyclodextrin complex. AAPS PharmSciTech 15:121–130
Ridhurkar DN, Ansari KA, Kumar D, Kaul NS, Krishnamurthy T et al (2013) Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties. Drug Dev Ind Pharm 39:1783–1792
Roos C, Dahlgren D, Berg S, Westergren J, Abrahamsson B et al (2017) In vivo mechanisms of intestinal drug absorption from aprepitant nanoformulations. Mol Pharm 14:4233–4242
Roos C, Dahlgren D, Sjogren E, Sjoblom M, Hedeland M et al (2018a) Jejunal absorption of aprepitant from nanosuspensions: role of particle size, prandial state and mucus layer. Eur J Pharm Biopharm 132:222–230
Roos C, Westergren J, Dahlgren D, Lennernas H, Sjogren E (2018b) Mechanistic modelling of intestinal drug absorption—the in vivo effects of nanoparticles, hydrodynamics, and colloidal structures. Eur J Pharm Biopharm 133:70–76
Sallas F, Darcy R (2008) Amphiphilic cyclodextrins—advances in synthesis and supramolecular chemistry. Eur J Org Chem 2008:957–969
Salustio PJ, Pontes P, Conduto C, Sanches I, Carvalho C et al (2011) Advanced technologies for oral controlled release: cyclodextrins for oral controlled release. Aaps Pharmscitech 12:1276–1292
Shono Y, Jantratid E, Kesisoglou F, Reppas C, Dressman JB (2010) Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm 76:95–104
Singare DS, Marella S, Gowthamrajan K, Kulkarni GT, Vooturi R et al (2010) Optimization of formulation and process variable of nanosuspension: an industrial perspective. Int J Pharm 402:213–220
Sodeifian G, Sajadian SA, Daneshyan S (2018) Preparation of aprepitant nanoparticles (efficient drug for coping with the effects of cancer treatment) by rapid expansion of supercritical solution with solid cosolvent (RESS-SC). J Supercrit Fluids 140:72–84
Sun J, Wang F, Sui Y, She Z, Zhai W et al (2012) Effect of particle size on solubility, dissolution rate, and oral bioavailability: Evaluation using coenzyme Q(1)(0) as naked nanocrystals. Int J Nanomed 7:5733–5744
Tobio M, Sanchez A, Vila A, Soriano II, Evora C et al (2000) The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf B Biointerfaces 18:315–323
Toziopoulou F, Malamatari M, Nikolakakis I, Kachrimanis K (2017) Production of aprepitant nanocrystals by wet media milling and subsequent solidification. Int J Pharm 533:324–334
Ünal H, d’Angelo I, Pagano E, Borrelli F, Izzo A et al (2015) Core–shell hybrid nanocapsules for oral delivery of camptothecin: formulation development, in vitro and in vivo evaluation. J Nanopart Res 17:1–13
Unal H, Ozturk N, Bilensoy E (2015) Formulation development, stability and anticancer efficacy of core-shell cyclodextrin nanocapsules for oral chemotherapy with camptothecin. Beilstein J Org Chem 11:204–212
Unal S, Aktas Y, Benito JM, Bilensoy E (2020) Cyclodextrin nanoparticle bound oral camptothecin for colorectal cancer: Formulation development and optimization. Int J Pharm 584:119468
Varan G, Varan C, Erdogar N, Hincal AA, Bilensoy E (2017) Amphiphilic cyclodextrin nanoparticles. Int J Pharm 531:457–469
Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ (2002) Design of biodegradable particles for protein delivery. J Control Release 78:15–24
Wang Y, Cui Y, Zhao Y, Zhao Q, He B et al (2018) Effects of surface modification and size on oral drug delivery of mesoporous silica formulation. J Colloid Interface Sci 513:736–747
Wu Y, Loper A, Landis E, Hettrick L, Novak L et al (2004) The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm 285:135–146
Ye Y, Zhang T, Li W, Sun H, Lu D, Wu B, Zhang X (2016) Glucose-based mesoporous carbon nanospheres as functional carriers for oral delivery of amphiphobic raloxifene: Insights into the bioavailability enhancement and lymphatic transport. Pharm Res 33:792–803
Zerkoune L, Angelova A, Lesieur S (2014) Nano-Assemblies of modified cyclodextrins and their complexes with guest molecules: Incorporation in nanostructured membranes and amphiphile nanoarchitectonics design. Nanomaterials 4:741–765
Zhang M, Li XH, Gong YD, Zhao NM, Zhang XF (2002) Properties and biocompatibility of chitosan films modified by blending with PEG. Biomaterials 23:2641–2648
This study was financially supported by the TUBITAK Scientific Research Project 216S773. Authors would like to thank Hacettepe Technology Transfer Center for advance editing.
Conflict of interest
The authors declare no conflicts of interest.
Research involving human and animal rights
This study was approved by the local ethics committee for animal experimentation of Hacettepe University. (Approval number, 2016/28–05).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Erdoğar, N., Akkın, S., Nielsen, T.T. et al. Development of oral aprepitant-loaded chitosan–polyethylene glycol-coated cyclodextrin nanocapsules: formulation, characterization, and pharmacokinetic evaluation. J. Pharm. Investig. (2021). https://doi.org/10.1007/s40005-020-00511-x
- Amphiphilic cyclodextrin
- Neurokinin-1 receptor antagonist
- Chemotherapy-induced nausea and vomiting